ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Volumetric Nanodroplet-Enhanced Ultrasound Surgery Combined with Immune Checkpoint Inhibition as a Cancer Therapy Platform.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Acoustically Activatable Drug-Loaded Nanodroplets for Mechanochemical Therapy in Solid Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Dual-Frequency Ultrasound Enhances Cavitation of Microdroplets for Controlled Scaffold Porosity in Tissue Engineering.ACS applied materials & interfaces · 2026Article
- Ultrasound-driven mechanical immunomodulation enhances tumor treatment sensitivity: advances from tumor mechanical immunobiology to immunotherapy applications.Frontiers in immunology · 2026Review
- Ultrasound-responsive micro/nanobubbles based intelligent theranostic systems for precision tumor therapy.Journal of nanobiotechnology · 2025Review
- Volumetric Nanodroplet-Enhanced Ultrasound Surgery Combined with Immune Checkpoint Inhibition as a Cancer Therapy Platform.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Ultrasound-assisted immunotherapy for malignant tumour.Frontiers in immunology · 2025Review
- Acoustic immune reprogramming: a novel paradigm for spatiotemporally controlled immune regulation using ultrasound-responsive nanoplatforms.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Immune checkpoint inhibitors hold promise, yet their efficacy in solid tumors is limited by the complex tumor microenvironment and the lack of immune cell infiltration. This study aims to enhance immunotherapy by combining anti PD-1 checkpoint inhibition therapy with nanodroplet-mediated histotripsy. The proposed method involves systemic injection of nanodroplets, which accumulate within tumors. These nanodroplets are then activated into cavitating gas bubbles using a rotating imaging probe, followed by low-frequency ultrasound application. This process induces tumor fractionation, facilitating the shift of the tumor microenvironment from cold to hot. Tumor ablation results show extensive lesions within the cancerous tissues, demonstrating the effectiveness of the ablation treatment. The combined approach of nanodroplets, ultrasound and anti PD-1 yielded a significant reduction in tumor growth compared to control groups. Immunohistochemistry analysis reveals an increase in F4/80+ macrophages and CD8+ T cells in the treated tumor group, indicating an enhanced immune response. F4/80+ macrophages reached 21.36% ± 3.4%, while CD8+ T-cell recruitment achieved 6.76% ± 4.5%, representing a 6.8- and a 5.5-fold increase compared to the control group, respectively. This approach demonstrates the potential to overcome key barriers in solid tumor treatment by combining precise mechanical disruption with systemic immune activation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.